Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Liabilities and Shareholders Equity of $293.6 million for Q1 2026, up 271.8% year-over-year from $79.0 million in Q1 2025, and down 19.55% on a QoQ basis from $365.0 million in Q4 2025.
Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $293.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
- Liabilities and Shareholders Equity came in at $293.6 million for Q1 2026 at Scilex Holding, down from $365.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $365.0 million in Q4 2025, with the low at $79.0 million in Q1 2025.
- Average Liabilities and Shareholders Equity over 5 years is $138.4 million, with a median of $101.3 million recorded in 2023.
- Across the five-year window, Liabilities and Shareholders Equity plunged 38.96% in 2023 and soared 292.65% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $86.5 million in 2022, then gained by 17.08% to $101.3 million in 2023, then decreased by 8.25% to $93.0 million in 2024, then jumped by 292.65% to $365.0 million in 2025, then declined by 19.55% to $293.6 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $293.6 million, $365.0 million, and $275.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 116.58 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.89 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 136.46 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.02 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 293.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.64 Mn |
| Dec 31, 2025 | 364.98 Mn |
| Sep 30, 2025 | 275.88 Mn |
| Jun 30, 2025 | 83.76 Mn |
| Mar 31, 2025 | 78.98 Mn |
| Dec 31, 2024 | 92.95 Mn |
| Sep 30, 2024 | 100.43 Mn |
| Jun 30, 2024 | 104.54 Mn |
| Mar 31, 2024 | 91.24 Mn |
| Dec 31, 2023 | 101.31 Mn |
| Sep 30, 2023 | 80.53 Mn |
| Jun 30, 2023 | 126.46 Mn |
| Mar 31, 2023 | 86.05 Mn |
| Dec 31, 2022 | 86.53 Mn |
| Sep 30, 2022 | 101.46 Mn |
| Jun 30, 2022 | 142.30 Mn |
| Mar 31, 2022 | 140.97 Mn |
| Dec 31, 2021 | 77.93 Mn |
| Sep 30, 2021 | 139.64 Mn |
| Jun 30, 2021 | 139.90 Mn |